Study On The Diagnostic Value Of Various Volume-Adjusted Psa Derivatives In Prostate Cancer In South Chinese Populations

Objective: We aim to investigate the differential value of volume-adjusted prostate specific antigen (PSA) derivatives in the diagnosis of prostate cancer. Method: A retrospective study was performed among 374 cases that needed to receive prostate biopsy procedure in our hospital from 2014.1.1 to 2015.10.31. All the patients received a 10-core systemic biopsy procedure with the trans-peritoneal access guided by transrectal ultrasound. Clinical parameters were documented, including PSA, prostate volume, pathological results, etc. Patients were divided into several subgroups, according to different PSA level and transrectal ultrasound findings. The diagnosis of prostate cancer was determined by the pathological evaluation of the biopsy specimen. Result: In the 374 cases, 164 cases (43.9%) were prostate cancer. 154 cases (41.2%) had visually suspicious lesion detected by transrectal ultrasound. 136 cases (36.4%) had a serum level of PSA <= 10 ng/ml. Transition zone PSA density showed a better diagnostic efficacy than PSA density and peripheral zone PSA density did in all subgroups, especially in PSA grey-zone (conventionally, 4-10 ng/ml). Besides, transition zone PSA density was elevated consistently with the rise of the grade groups of Gleason score. Conclusion: Transition zone PSA density can be used as a complementary prostate specific antigen derivative for the detection of prostate cancer, and therefore it may help to reduce the incidence of the unnecessary biopsy. In addition, it is a potential predictor for the prognosis of prostate cancer, to some extent.